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Background: Pulmonary arterial hypertension (PAH) is a proliferative arteriopathy associated with a glycolytic shift during
heart metabolism. An increase in glycolytic metabolism can be detected in the right ventricle during PAH. Expression
levels of glycolysis genes in the right ventricle during glycolysis that occur in monocrotaline (MCT)-induced pulmonary
hypertension (PH) remain unknown.
Methods: PH was induced by a single subcutaneous injection of MCT (50 mg/kg) into rats, eventually causing right heart
failure. Concurrently, a control group was injected with normal saline. The MCT-PH rats were randomly divided into three
groups according to MCT treatment: MCT-2 week, 3 week, and 4 week groups (MCT-2w, 3w, 4w). At the end of the study,
hemodynamics and right ventricular hypertrophy were compared among experimental groups. Expression of key
glycolytic candidate genes was screened in the right ventricle.
Results: We observed an increase in mean pulmonary arterial pressure, right ventricular systolic pressure and right
ventricular hypertrophy index three weeks following MCT injection. Alterations in the morphology and structure of right
ventricular myocardial cells, as well as the pulmonary vasculature were observed. Expression of hexokinase 1 (HK1) mRNA
began to increase in the right ventricle of the MCT-3w group and MCT-4w group, while the expression of lactate
dehydrogenase A (LDHA) was elevated in the right ventricle of the MCT-4w group. Hexokinase 2(HK2), pyruvate
dehydrogenase complex α1 (PDHα1), and LDHA mRNA expression showed no changes in the right ventricle. HK1
mRNA expression was further confirmed by HK1 protein expression and immunohistochemical analyses. All findings
underlie the glycolytic phenotype in the right ventricle.
Conclusions: There was an increase in the protein and mRNA expression of hexokinase-1 (HK1) three and four weeks
after the injection of monocrotaline in the right ventricle, intervention of HK1 may be amenable to therapeutic
intervention.
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Pulmonary arterial hypertension (PAH) is a multifactorial
and progressive disease characterized by a sustained in-
crease in pulmonary vascular resistance, eventually leading
to right heart failure and death [1]. Although the primary* Correspondence: zhengyang@jlu.edu.cn; jingzhicheng@gmail.com
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right ventricle pressure overload stimulates right ven-
tricular hypertrophy and right ventricular failure. The
leading cause of death in PAH is right ventricular failure
[2,3]. Most researchers and medical professionals agree
that the right ventricle (RV) response to pulmonary hyper-
tension (PH) is a major determinant of survival, and a
change in myocardial metabolism is a prominent feature
of RV dysfunction [4].
Increased right ventricular fluorodeoxyglucose (FDG)
uptake has also been described in patients with PAH [4,5],
reflecting a shift from oxidative to glycolytic metabolism.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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pulmonary hypertension (induced by monocrotaline
(MCT) or chronic hypoxia) [6-8] and in models of RV
pressure overload induced by pulmonary artery banding
[9]. The glycolytic shift was evidenced by an increased
uptake of FDG on PET and by direct measurement of
metabolism in isolated working RV hearts, and the
corrected RV FDG accumulation was decreased after the
treatment with epoprostenol in accordance with the de-
gree of reduction in the pulmonary vascular resistance [5].
Furthermore, recent animal data indicated that metabolic
derangements in the RV contribute to RV dysfunction
[7,9,10]. However, the mechanism of glycolytic metabol-
ism in the RV is still unknown. Whether the glycolytic
pathway and glycolysis-related genes participate in PAH
has yet to be elucidated; moreover, little is known about
the details of the molecular mechanism of PAH
development.
In the present study we used MCT-treated rats as an
experimental model of PH induced RV failure. MCT is a
pyrrolizidine alkaloid, and its bioactive metabolite select-
ively injures the vascular endothelium of lung vessels.
Progressive pulmonary vasculitis leads to increasing
vascular resistance and a gradual rise in arterial pressure
after a single dose of MCT. The increase in RV afterload
induces hypertrophy and eventual failure. The present
study investigates the hypothesis that the expression of
glycolysis genes in the RV in MCT-PH rats were
increased and aims to screen glycolysis relevant genes ,
including hexokinase1, hexokinase2, and hexokinase3
(HK1, HK2 and HK3), phosphofructokinase (PFK),
pyruvate kinase (PK), pyruvate dehydrogenase complex
(PDHα1 PDHα1 PDHβ), lactate dehydrogenase (LDHA,
LDHB, LDHC and LDHD) and glyceraldehyde-phosphate
dehydrogenase (GAPDH; housekeeping gene) using real




Forty-eight adult male Sprague–Dawley rats (body
weights, 200 – 220 g) were divided into four groups:
control, MCT-2 week, MCT-3 week and MCT-4 week.
Control rats received a single subcutaneous injection of
saline (n = 12; saline group) and PH was induced by a
single subcutaneous injection of monocrotaline (MCT;
50 mg kg-1; Sigma, St. Louis, MO, USA) to cause right
heart failure. All experimental procedures were per-
formed in accordance with the Guide for the Care and
Use of Laboratory Animals (US National Institutes of
Health Publication Number 85–23; revised 1996), and
were approved by the Institutional Committee for Use
and Care of Laboratory Animals of Tongji University.Haemodynamic measurements
After weighing, all rats were anaesthetized with IP 6%
chloral hydrate (6 ml/kg), and haemodynamic parame-
ters were measured by a polygraph system (PowerLab 8/
30; AD Instruments, Bella Vista, NSW, Australia). Ad-
equate anaesthesia was monitored by the withdrawal re-
sponse to a paw pinch and respiration monitoring. After
a tracheotomy, a polyethylene-50 catheter was inserted
via the right external jugular vein into the pulmonary
artery, The haemodynamic parameter assessment in-
cluded mean pulmonary arterial pressure (mPAP) and
right ventricular systolic pressure (RVSP) at the end of
the study.
Right ventricular hypertrophy and morphometric analyses
of pulmonary arteries and right ventricle
The weights of the free-wall of the RV and the left
ventricle plus septum (LV+S) were measured separately,
and the ratio RV/(LV+S) was calculated as the RV hyper-
trophy index.
According to the prospective protocol, the lungs and
RV were flushed with ice-cold saline following assess-
ment of haemodynamic parameters, and rats were then
euthanized prior to morphometric analyses. Sections
from the upper left lung tissue and the right ventricular
tissues were paraffin-embedded and stained with haema-
toxylin – eosin (H & E). Arteries of 15–200 μm and
right ventricular tissues were evaluated at 400× magnifi-
cation and analyzed using the Intel Integrated Perform-
ance Primitives version 5.0 software (Santa Clara, CA,
USA).
Immunohistochemical analyses
HK1-positive myocardial cells were assessed using HK1
polyclonal antibody staining (1:1000 dilution; Thermo,
USA). The number of HK1-positive cells in 10 fields for
each section was quantitatively evaluated as a percent of
that total of cells at a magnification of 400× in a blind
manner [11].
Total-RNA extraction and first strand cDNA synthesis
Total RNA was isolated from the frozen tissue of right
ventricles using the Thizol method [12]. The RNA
concentration was determined spectrophotometrically
on the basis of absorbance at 260 nm (Beckman, DU800,
USA). First strand cDNA was synthesized from total-
RNA by using a RT-PCR kit (Takara). The candidate
genes were detected using quantitative real-time fluores-
cent quantitative reverse transcription-polymerase chain
reaction (qRT-PCR) in the right ventricular tissue.
Samples were added to a microwell plate with TaqMan
probes and RT-PCR reagents (Applied Biosystems,
Foster City, CA). qRT-PCR was performed with an ABI
PRISM 7500 Sequence Detector (Applied Biosystems,
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PFK, PK, PDHα1 PDHα1 PDHβ, LDHA, LDHB, LDHC
and LDHD and GAPDH were used. The primers synthe-
sized by ShengGong biological technology in Shanghai.
Primer sequences are shown in Table 1.Western blot analyses
Ventricular tissue homogenates were prepared and sub-
jected to electrophoresis on sodium-dodecyl-sulfate poly-
acrylamide gels, and then transferred onto polyvinylidene
fluoride membranes. Membranes were blocked with 5%
skimmed milk or 1% bovine serum albumin, and probed
with a monoclonal antibody targeting anti-HK1 (1:1000
dilution; Thermo, USA), or anti-GAPDH (1:8000 dilution;
ProteinTech, Chicago, IL, USA), followed by the matched
secondary antibody (1:2000 dilution; ProteinTech, Chicago,
IL, USA). Immunopositive spots were visualized using
ECL-Plus™ (Amersham Biosciences, Chalfont St Giles, UK).Statistical analyses
Data were analyzed using the Statistical Package for the
Social Sciences Ver. 15.0 software (SPSS Inc., Chicago,
IL, USA). A one-way ANOVA was used to test for
differences among treatment groups, followed by multiple
comparisons with the least-significant difference method.
The data are reported as mean ± SD of at least three inde-
pendent experiments. Statistical analysis was performed
using unpaired Student’s t-tests to determine the signifi-
cance between the two means. A probability of P < 0.05
















MCT increased mPAP and RVSP and induced right
ventricular hypertrophy
Compared to control group, rats challenged with MCT
consistently developed significant PAH with higher mPAP
and RVSP in the MCT-3 week and MCT-4 week groups
(RVSP:control:27 ± 1 mmHg, MCT-2w:30 ± 2 mmHg;
MCT-3w: 52 ± 6 mmHg; MCT-4w: 54 ± 5 mmHg; mPAP:
control: 24 ± 1 mmHg; MCT-2w:26 ± 3 mmHg; MCT-
3w:45 ± 6 mmHg; MCT-4w:47 ± 5 mmHg, respectively),
and the parameters did not rise over time (Figure 1A and
B). The ratio of RV free-wall weight to LV + S weight in
the MCT group was significantly increased compared with
the control group [control group (0.186 ± 0.025), MCT-
3 week group (0.285 ± 0.073, P < 0.05) and MCT-4 week
group (0.329 ± 0.052, P < 0.01)]. Moreover, RV hyper-
trophy positively correlated with MCT treatment time.Morphology of right ventricles and pulmonary
vasculature
H & E results show that the pulmonary vasculature was
thicker following MCT exposure. Remodeled small pul-
monary arteries can be observed throughout the lungs
(Figure 2A). Also, the myocardial cell nuclei of the
control group were in alignment in the RV, muscle fiber
directions were consistent, and myocardial cell nuclei
were clear. When extending the MCT treatment time
(after 3 weeks), the myocardial cells were disordered,
muscle fiber direction was unclear, and the myocardial
cells sarcoplasm dissolved to increase interstitial fluid
(Figure 2B).quences used for amplification using real-time PCR
PCR products














Figure 1 Monocrotaline (MCT) deteriorateshaemodynamics in rats. A: Mean pulmonary artery pressure (mPAP); B: right ventricular systolic
pressure (RVSP); MCT-2w : MCT-2 week group; MCT-3w : MCT-3 week group; MCT-4w : MCT-4 week group; Data shown are means ± SD of 8 –10
rats per group. **P < 0.01 vs. control.
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right ventricles
Compared with the control group, gene expression of
LDHA was up-regulated more than threefold in the
MCT-4 week group, while HK1 gene expression raised
significantly in the MCT-3 week group (increased ~2.5
fold). Gene expression was clearly higher in the MCT-
4 week group (increased more than threefold), and HK2
and PDHα1 did not present any difference in expressed
genes (Figure 3), as compared to the control group.
Expression of HK1 protein in right myocardial cells and
the pulmonary vasculature
Immunohistochemical results showed that HK1-positive
cell expression gradually increased when correlated with
MCT treatment time in the RV myocardial cells. The
levels of HK1-positive cell expression increased to 33%Figure 2 The change of morphology of lung tissue and right ventriclein the MCT-3w group, and to 39% in the MCT-4w
group, compared with the control group (8%) (Figure 4A
and B). However, consistent with HK1 gene expression,
as compared with the control group, HK1 protein ex-
pression was significantly increased in the MCT-3 week
(increased ~ 1.6 fold) and MCT-4 week groups (in-
creased ~1.8 fold) in right ventricular tissue (Figure 4C).
Discussion
It is important that new treatments for PAH address not
only the pulmonary vascular pathology, but also the
structure and function of RV in PH. For the RV myo-
cardium, it has been shown that myocardial energy sub-
strate utilization is altered in association with the
development of pathological forms of ventricular hyper-
trophy. In this study, we first attempted to verify the acti-
vation of these genes relevant to the glycolytic pathway inin rats with MCT treatment time. A: lung tissue; B: right ventricle.
Figure 3 The expression of the genes in the glycolytic pathway
in right ventricles. HK1: hexokinase 1; HK2: hexokinase 2; LDHA:
lactate dehydrogenase A; PDHα1: pyruvate dehydrogenase complex
α1. *P < 0.05 vs. controls; #P < 0.05 vs. MCT-3w.
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genes about metabolic pathway in RV, trying to show that
some genes are aggravating one of the causes of right
heart failure.
Glycolysis involves either glucose or glycogen degrad-
ing pyruvate or lactate in the cytoplasm, while releasing
a small amount of energy for use. There are three irre-
versible steps in glycolysis, which are highly exothermic
reactions. Our candidate loci included three irreversible
rate-limiting enzymes in glycolysis: HK, PFK, PK; the first
key enzyme PDH locates the mitochondrial citric acid
cycle; and the final product of glycolysis is LDH. Finally,
we sought to clarify the possible molecular mechanisms
underlying PAH and its association to the glycolytic path-
way and glycolysis-related genes.
There was a significant elevation of mPAP and RVSP,
and right heart hypertrophy index markedly increasedFigure 4 The expression of HK1 protein is evaluated in right ventricu
ventricle; B: percentage of HK1-positive myocardial cells in right ventricles;
*P < 0.05 vs. controls.with MCT treatment time. Our study examined different
genes in the RV tissues of the glycolytic pathway. We
found that both HK1 gene and protein expression were
increased, which is one of the three speed limiting en-
zymes in the glycolytic pathway. HK1 is the first of the
glycolytic pathway speed limiting enzymes, and its expres-
sion can cause the downstream cascade amplification re-
action to provide more ATP to remodel myocardial cells.
LDHA gene expression was up-regulated in the right ven-
tricular tissues of the MCT-4 week group, and an increase
in LDHA expression occurred after HK1 expression in-
creased. However, Drake JI and colleagues [13] screened
and compared different gene expressions between right
ventricle hypertrophy and heart failure using gene chip
technology, they found HK1 and PFK gene expression was
increased in the failing RV compared with the hypertro-
phied RV.
Glycolytic shift seems to be of significant biological
impact in the right ventricle affected by PAH. The
reasons of glycolytic pathway activation is the body is in
“pseudoanoxic” condition, it may be due to the mitochon-
drial damage, the expression of superoxide dismutase was
lower, it leaded to decreased of hydrogen peroxide in
downstream [14]. In patients with PAH, the body feels
hypoxic under normal oxygen conditions, leading to the
activation of hypoxia-inducible factor α1, which inhibits
the mitochondrial electron transport chain and activates
pyruvate dehydrogenase kinase (PDK) (which can inhibit
PDH), inhibits the Krebs cycle, and reduces ATP produc-
tion [15]. This may lead to myocardial ischemia and
perpetuate right heart failure in PAH. Studies in animal
models of PH suggest that dichloroacetate (DCA) (in-
creasing oxidation of glucose) increases cardiac contractil-
ity ex vivo and in vivo [8,16,17]. Restitution of oxidativelar tissue. A: The immunohistochemical expression of HK1 in right
C: The expression of HK1 protein in right ventricle. HK1: hexokinase 1;
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efficient in several animals of PAH. Piao and others have
used Fawn-Hooded rats, which develop spontaneous PAH,
to demonstrate that oral DCA can increase oxidation of
glucose, ATP production, improve right heart function,
and increase cardiac output [10].
Overall, in the present study we have demonstrated the
ability to screen for candidate genes within the metabolic
pathway in the RV. We found that the level of HK1 mRNA
was increased in the RV of MCT-PH rats, and HK1 expres-
sion correlated with MCT treatment time. In addition, con-
sistent with the expression of HK1 mRNA, the expression
of HK1 protein was increased in the RV of MCT-PH rats.
However, elucidation of the exact mechanism by which
HK1 mRNA and protein were increased in the RV of
MCT-PH rats requires further investigation. The aims of
future research should include HK1 studies involving other
PAH animal models, as well as in vivo and in vitro studies
of related biochemical pathways to evaluate whether HK1
inhibitors can reduce mPAP, RVSP, RVHI and ameliorate
PAH. The characterization of the mechanisms underlying
the metabolism in PAH, such as cancer, has become
emerging targets for novel diagnostic and therapeutic
approaches that may have relevance to PH.
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